International Journal of Pharma and Bio Sciences
    ISSN 0975-6299

Int J Pharm Bio Sci Volume 14 Issue 2, April-June, Pages:27-36

Lipid Profile in Geriatric Patients with Diabetic Nephropathy: A Case-Control Study

Dr Keshavamurthy HR, Dr. Shivakumar, Dr Vinodkumar and Dr Prashantkumar

Diabetic nephropathy is one of the common causes of end-stage kidney disease (ESKD). It is a major microvascular complication that occurs among patients with diabetes. Dyslipidaemia is a modifiable cardiovascular risk factor. Hence early intervention can delay or prevent the progression of the disease. Till now, studies were done on lipid profiles in diabetic patients or nephropathy patients, or obese hypertensive patients. The study's novelty is that we are measuring the lipid profile in diabetic nephropathy patients. The current study aims to assess lipid profiles among diabetic nephropathy patients. The objectives of the study are to compare lipid profiles among diabetic nephropathy patients with diabetic nonnephropathy patients and to identify risk factors associated with abnormal lipid profiles in diabetic nephropathy patients. This study was carried out among 50 samples of diabetic nephropathy patients(cases) and 50 samples of diabetic patients without nephropathy (controls).The study samples were taken from patients who attended the outpatient unit of the General Medicine department at a tertiary care center named Sri Siddhartha Medical College, Tumkur, Karnataka, India. Fasting serum total cholesterol (TC), triglycerides (TGs), high-density lipoprotein cholesterol (HDL-C), and lowdensity lipoprotein-cholesterol (LDL-C) were measured. Results showed that most of the patients were males. Most of the patients were aged 61 to 70 years. TC, LDL-C, and TGs were significantly more among cases than controls. HDL-C was significantly lower among cases compared to controls in the current study. We conclude that diabetes, being a part of metabolic syndrome, may not cause abnormal lipid profiles. Still, the presence of nephropathy or renal damage along with diabetes increases the risk of hyperlipidemia, which keeps the patients at high risk of cardiovascular disorders.

Keywords: Case-control study, Diabetic Nephropathy, End Stage Kidney Disease, High-density lipoprotein cholesterol, Lipid Profile, Total cholesterol
Full HTML:
  1. Rabkin R. Diabetic nephropathy. Clin Cornerstone. 2003;5(2):1-11. doi: 10.1016/s1098-3597(03)90014-7, PMID 12800476.
  2. Umanath K, Lewis JB. Update on diabetic nephropathy: core curriculum 2018. Am J Kidney Dis. 2018 Jun;71(6):884-95. doi 10.1053/j.ajkd.2017.10.026, PMID 29398179.
  3. Genuth S, Eastman R, Kahn R, Klein R, Lachin J, Lebovitz H et al. Implications of the United Kingdom prospective diabetes study. Diabetes Care. 2003 Jan;26;Suppl 1:S28-32. doi: 10.2337/diacare.26.2007.s28, PMID 12502617.
  4. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20;345(12):861-9. doi: 10.1056/NEJMoa011161, PMID 11565518.
  5. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851-60. doi: 10.1056/NEJMoa011303, PMID 11565517.
  6. Page MR, The JNC. The JNC 8 hypertension guidelines: an in-depth guide. Am J Manag Care. 2014;20(1);Spec No.(1 Spec): E8:E8. PMID 25618230.
  7. Armstrong C, Joint National Committee. JNC8 guidelines for the management of hypertension in adults. Am Fam Phys. 2014 Oct 01;90(7):503-4. PMID 25369633.
  8. Menne J, Ritz E, Ruilope LM, Chatzikyrkou C, Viberti G, Haller H. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation. J Am Heart Assoc. 2014;3(2):e000810. (PMC Free article). doi 10.1161/jaha.114.000810, PMID 24772521.
  9. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of finer enone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial. JAMA. 2015 Sep 01;314(9):884-94. doi 10.1001/jama.2015.10081, PMID 26325557.
  10. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. PMID 26378978.
  11. Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium-glucose co-transporter 2 (SGLT2) inhibitors: A state-of-the-art review. JACC Basic Transl Sci. 2020 Jun 22;5(6):632-44. doi 10.1016/j.jacbts.2020.02.004, PMID 32613148, PMCID PMC7315190.
  12. Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, et al. Comprehensive management of cardiovascular risk factors for Adults with Type 2 diabetes: A scientific statement from the American Heart Association. Circulation. 2022;145(9):e722-59. doi 10.1161/CIR.0000000000001040, PMID 35000404.
  13. Kawanami D, Matoba K, Utsunomiya K. Dyslipidemia in diabetic nephropathy. Ren Replace Ther. 2016;2(1):16. doi 10.1186/s41100-016-0028-0.
  14. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol. 2005;16(2):529-38. doi 10.1681/ASN.2004080656, PMID 15625072.
  15. Chijioke A, Makusidi AM, Shittu OA, Sanni MA, Biliaminu SA, Abdul-Rahman S, et al. Pattern of lipid profile in dialysis naïve patients from Ilorin, Nigeria. Internet J Nephrol. 2011;6(1):1-7.
  16. Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. 2021 Canadian Cardiovascular Society guidelines for managing dyslipidemia to prevent cardiovascular disease in adults. Can J Cardiol. 2021;37(8):1129-50. doi 10.1016/j.cjca.2021.03.016, PMID 33781847.
  17. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK. Net al, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines. J Am Coll Cardiol. 2019 Jun 25;73(24):e285-350. doi: 10.1016/j.jacc.2018.11.003. Erratum in: J Am Coll Cardiol. 2019 Jun 25;73(24):e285-350. doi 10.1016/j.jacc.2018.11.003, PMID 30423393.
  18. Karguppikar M, Oza C, Shah N, Khadilkar V, Gondhalekar K, Khadilkar A. Prevalence of nephropathy in Indian children and youth with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2022 Mar 21;35(5):585-92. doi: 10.1515/jpem-2021-0644, PMID 35304981.
  19. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010 Jan;33;Suppl 1(Suppl 1):S62-9. doi 10.2337/dc10-S062. Erratum in: Diabetes Care. 2010 Apr;33(4):e57. doi: 10.2337/dc09-2368, PMID 20351224, PMCID PMC2797383.
  20. KDIGO. Clinical Practice Guideline of evaluation and management of CKD. Kidney Int Suppl 2013. 2012;3(1):1-150.
  21. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20(4):470-5. doi: 10.1093/clinchem/20.4.470, PMID 4818200.
  22. Fossati P, Prencipe L. Serumtriglyceriderides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982;28(10):2077-80. doi: 10.1093/clinchem/28.10.2077, PMID 6812986.
  23. Warnick GR, Nauck M, Rifai N. Evaluation of methods for measurement of HDL-cholesterol: from ultracentrifugation to Homogeneous assays. Clin Chem. 2001;47(9):1579-96. doi: 10.1093/clinchem/47.9.1579, PMID 11514391.
  24. Sugiuchi H, Uji Y, Okabe H, Irie T, Uekama K, Kayahara N et al. I.e., T et al. Directly measured high-density lipoprotein cholesterol in serum with polyethylene glycol-Modified Enzymes and Sulfatedα-cyclodextrin. Clin Chem. 1995;41(5):717-23. doi: 10.1093/clinchem/41.5.717, PMID 7729051.
  25. Sahu S. Calculation of VLDL-cholesterol from triglycerides and total cholesterol levels. Biomedicine. 2008;28:219-21.
  26. Kidney disease: improving global outcomes (KDIGO) lipid work group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013;3:259-305. Google Scholar.
  27. Krolewski AS, Warram JH, Christlieb AR. Hypercholesterolemia: a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int Suppl. 1994;45:S125-31. PMID 8158881, Google Scholar.
  28. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, et al. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int. 2003;64(3):817-28. doi: 10.1046/j.1523-1755.2003.00164.x, PMID 12911531, Google Scholar.
  29. Roumeliotis S, Georgians PI, Roumeliotis A, Eleftheriadis T, Stamou A, Manolopoulos VG, et al. Oxidized LDL modifies the association between proteinuria and deterioration of kidney function in proteinuric diabetic kidney disease. Life (Basel) [PMC Free article]. 2021;11(6):504. doi: 10.3390/life11060504, PMID 34072583 [CrossRef]. Google Scholar.
  30. Yang Y, Xu P, Liu Y, Chen X, He Y, Feng J. Vascular inflammation, atherosclerosis, and lipid metabolism and the occurrence of non-high albuminuria diabetic kidney disease: A cross-sectional study. Diabetes Vasc Dis Res. 2021;18(1):1479164121992524. doi: 10.1177/1479164121992524. (PMC Free article). PMID 33567895 [CrossRef]. Google Scholar.
  31. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American Heart Association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120(16):1640-5. doi: 10.1161/CIRCULATIONAHA.109.192644, PMID 19805654.
  32. Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens. 2004;19:679-82.
  33. Bhatti MS, Akbri HZ, Shakoor M. Lipid profile in obesity. J Ayub Med Coll Abbotabad. 2001;19(1):31-3.
  34. Szczygielska A, Widomska S, Jaraszkiewicz M, Knera P, Muck S. Blood lipid profile in obese or overweight patients. Ann Univ Mariae Curie Skoldowska Med. 2003;58(2):343-9.
  35. Adejumo OA, Okaka EI, Madumezia G, Okwuonu CG, Ojogwu LI. Assessment of some cardiovascular risk factors in predialysis chronic kidney disease patients in Southern Nigeria. Niger Med J. 2015 Nov-Dec;56(6):394-9. doi: 10.4103/0300-1652.171616, PMID 26903696.
  36. Patil S, Kumar VA, Subramani S. To evaluate Lipid Profiles in Patients with Chronic Kidney Disease in RajaRajeswari Medical College and Hospital, Bengaluru, Karnataka, India. J Med Sci. 2018;4(2):31-4. doi: 10.5005/jp-journals-10045-0080.
  37. Palazhy S, Viswanathan V. Lipid abnormalities in type 2 diabetes mellitus patients with overt nephropathy. Diabetes Metab J. 2017 Apr;41(2):128-34. doi 10.4093/dmj.2017.41.2.128, PMID 28447439, PMCID PMC5409011.
  38. Mm S, M S, Bitla A, A M, S A. Atherogenic dyslipidemia in diabetic nephropathy: lipoprotein (a), lipid ratios and atherogenic index. Int J Res Med Sci. 2013;1(4):455-9. doi: 10.5455/2320-6012.ijrms20131129, Google Scholar.
  39. Jisieike-Onuigbo NN, Unuigbe EI, Kalu OA, Oguejiofor CO, Onuigbo PC. Prevalence of dyslipidemia among adult diabetic patients with overt diabetic nephropathy in Anambra state south-east Nigeria. Niger J Clin Pract. 2011;14(2):171-5. doi: 10.4103/1119-3077.84009, PMID 21860134, Google Scholar.
  40. Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P. The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant. 1998;13(11):2833-41. doi 10.1093/ndt/13.11.2833, PMID 9829487, Google Scholar.
  41. Mohapatra D, Damodar KS. Glycaemia status, lipid profile and renal parameters in progressive diabetic neuropathy. J Clin Diagn Res. 2016;10(9): CC14-7. doi 10.7860/JCDR/2016/20004.8515, PMID 27790428.
  42. Reiber GE, Pecoraro RE, Koepsell TD. Risk factors for amputation in patients with diabetes mellitus. A case-control study. Health Services Research & Development. Ann Intern Med. 1992;117(2):97-105. doi 10.7326/0003-4819-117-2-97, PMID 1605439.
  43. Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL. Elevated triglycerides correlate with the progression of diabetic neuropathy. Diabetes. 2009;58(7):1634-40. doi: 10.2337/db08-1771, PMID 19411614.
  44. Henry RR. Preventing cardiovascular complications of type 2 diabetes: focus on lipid management. Clin Diabetes. 2001;19(3):113-20. doi: 10.2337/diaclin.19.3.113.
[Download PDF]
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy
Pharmaceutical Fields
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmaceutics
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Novel drug delivery system
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Nanotechnology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacognosy
© Copyright 2009-2015 IJPBS, India. All rights reserved. Specialized online journals by ubijournal. Website by Ubitech Solutions
         Home I Contact I Terms & Conditions